Src and focal adhesion kinase as therapeutic targets in cancer

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Over the past few years small molecule inhibitors of both Src family kinases and focal adhesion kinase (FAK) have entered clinical studies for the treatment of solid tumours. These adhesion-linked kinases are involved in a number of pathways that have impact on the behaviour of tumour cells and the challenge is now, how to take these forward in the clinical setting.
Original languageEnglish
Pages (from-to)427-32
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume8
Issue number4
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Dive into the research topics of 'Src and focal adhesion kinase as therapeutic targets in cancer'. Together they form a unique fingerprint.

Cite this